May 6 |
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
|
May 2 |
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
|
Apr 24 |
Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
|
Apr 22 |
Lantern Pharma Receives Regulatory Approval to Expand Harmonicâ„¢ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
|